Abstract
This is a review of the epidemiology and management of infectious complications in contemporary management of chronic leukemias. Patients with chronic leukemias typically are affected by nuisance infections due to the underlying hematologic condition, particularly hypogammaglobulinemia in CLL patients. With active treatment, particularly those agents that cause defects in cell-mediated immunity, the incidence of opportunistic infections increases although endogenous bacterial, mycobacterial, and fungal infections also occur. Exogenous treatment with immunoglobulin and antimicrobial prophylaxis, particularly anti-Pneumocystis prophylaxis, may be indicated in select patients. Routine vaccinations should be maintained in these patients and vaccination early in the course of treatment may result in improve protection.
Keywords: Chronic myelogenous leukemia (CML), chronic granulocytic leukemia (CGL), chronic lymphoid leukemia (CLL), hypogammaglobulinemia, opportunistic infection, Pneumocystis, anti-Pneumocystis prophylaxis, B-cell chronic, white blood cells, alkylating, prednisone, rituximab, alemtuzumab, hairy cell leukemia, neutropenia, monocytopenia, T-cell dysfunction, Sweet's syndrome, chronic myelogenous, myeloid, stem cells, chronic granulocytic leukemia, Allogeneic hematopoietic stem cell, mycobacteria, Aspergillus, legionellosis, salmonellosis, toxoplasmosis, listeriosis, Listeria, Pas-teurella multocida tracheobronchitis, Toxoplasma cyst, Cryptococcus, Chlamydophila psittaci
Infectious Disorders - Drug Targets
Title: Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Volume: 11 Issue: 1
Author(s): Jo-Anne H. Young
Affiliation:
Keywords: Chronic myelogenous leukemia (CML), chronic granulocytic leukemia (CGL), chronic lymphoid leukemia (CLL), hypogammaglobulinemia, opportunistic infection, Pneumocystis, anti-Pneumocystis prophylaxis, B-cell chronic, white blood cells, alkylating, prednisone, rituximab, alemtuzumab, hairy cell leukemia, neutropenia, monocytopenia, T-cell dysfunction, Sweet's syndrome, chronic myelogenous, myeloid, stem cells, chronic granulocytic leukemia, Allogeneic hematopoietic stem cell, mycobacteria, Aspergillus, legionellosis, salmonellosis, toxoplasmosis, listeriosis, Listeria, Pas-teurella multocida tracheobronchitis, Toxoplasma cyst, Cryptococcus, Chlamydophila psittaci
Abstract: This is a review of the epidemiology and management of infectious complications in contemporary management of chronic leukemias. Patients with chronic leukemias typically are affected by nuisance infections due to the underlying hematologic condition, particularly hypogammaglobulinemia in CLL patients. With active treatment, particularly those agents that cause defects in cell-mediated immunity, the incidence of opportunistic infections increases although endogenous bacterial, mycobacterial, and fungal infections also occur. Exogenous treatment with immunoglobulin and antimicrobial prophylaxis, particularly anti-Pneumocystis prophylaxis, may be indicated in select patients. Routine vaccinations should be maintained in these patients and vaccination early in the course of treatment may result in improve protection.
Export Options
About this article
Cite this article as:
H. Young Jo-Anne, Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias, Infectious Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152611794407755
DOI https://dx.doi.org/10.2174/187152611794407755 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member
Current Gene Therapy Current Concepts in the Diagnosis and Treatment of Type 1 and Type 2 Autoimmune Pancreatitis
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacotherapy of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Jean-Baptiste de Sénac’s (1693-1770) Important Work on Cardiology and Valvular Disorders
Current Pharmaceutical Design The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Proteomic Analysis of Liver Preservation Solutions Prior to Liver Transplantation
Current Proteomics Endovascular Therapies for Type B Aortic Dissection
Cardiovascular & Hematological Disorders-Drug Targets Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Current Pharmaceutical Design Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Prevention of Cardiovascular Complications in the Marfan Syndrome
Vascular Disease Prevention (Discontinued) Neurobiological Influences on Recovery from Traumatic Brain Injury: The Role of Genetic Polymorphisms
Current Pharmaceutical Design A Review of Macrolide Treatment of Atherosclerosis and Abdominal Aortic Aneurysms
Current Drug Targets - Infectious Disorders Matrix Metalloproteinases as Drug Targets in Preeclampsia
Current Drug Targets Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Role of Pericytes in Neurovascular Unit: Emphasis on Stroke
Current Drug Targets Editorial (Thematic Issue: Frontiers in Atherosclerosis, Heart Disease and Diabetes)
Cardiovascular & Hematological Disorders-Drug Targets The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design The Obesity-associated Risk in Open and Endovascular Repair of Abdominal Aortic Aneurysm
Current Pharmaceutical Design Porphyrin-Photosensitized Processes: Their Applications in the Prevention of Arterial Restenosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology